INTEGRITY AGREEMENT
BETWEEN THE
OFFICE OF INSPECTOR GENERAL
OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AND
ASAD U. QAMAR, M.D.

I. PREAMBLE

Asad U. Qamar, M.D. (Qamar) hereby enters into this Integrity Agreement (IA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). This IA applies to Qamar, any entity that provides items or services that will be billed to Federal health care programs in which Qamar has an ownership or control interest, as defined in 42 U.S.C. § 1320a-3(a)(3), at any time during the term of the IA, including but not limited to the Institute for Cardiovascular Excellence, PLLC (ICE), and to any other Covered Persons of Qamar as defined in Section II.C. Contemporaneously with this IA, Qamar is entering into a Settlement Agreement with the United States.

II. TERM AND SCOPE OF THE IA

A. This IA shall have a term of three years from the Effective Date. The Effective Date shall be the date on which the provider becomes reinstated to the federal health care programs. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.”

B. Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1) Qamar’s final annual report; or (2) any additional materials submitted by Qamar pursuant to OIG’s request, whichever is later.

C. The term “Covered Persons” includes:

1. Qamar and all owners, partners, associates, and employees of Qamar;
2. all contractors, agents, and other persons who furnish patient care items or services or who perform billing or coding functions (the employees of any third party billing company that submits claims to the Federal health care programs on behalf of Qamar shall not be considered Covered Persons, provided that Qamar and the third party billing company provide the certifications required by Section III.H) on behalf of Qamar;

3. all employees of any entity that provides items or services that will be billed to Federal health care programs in which Qamar has an ownership or control interest (as defined in 42 U.S.C. § 1320a-3(a)(3)) at any time during the term of this IA, including but not limited to ICE, and any contractors, agents, or other persons who provide patient care, items or services or who perform billing or coding functions on behalf of such entity.

III. INTEGRITY OBLIGATIONS

Qamar shall establish and maintain a Compliance Program that includes the following elements:

A. Posting of Notice

Within 60 days after the Effective Date, Qamar shall post in a prominent place accessible to all patients and Covered Persons a notice that provides the HHS OIG Fraud Hotline telephone number (1-800-HHS-TIPS) as a confidential means by which suspected fraud or abuse in the Federal health care programs may be reported.

B. Independent Cardiology Consultant

Within 60 days of the Effective Date, Qamar shall engage, and maintain for the term of this IA, an Independent Cardiology Consultant (ICC). The ICC shall be an interventional cardiologist who is certified by the American Board of Internal Medicine in cardiology and shall have expertise in the rules governing submission of claims to Federal health care programs for arterial and vascular procedures. The ICC shall be responsible for utilization review and oversight of quality of care matters for Qamar, including but not limited to performance improvement, quality assessment, patient safety, training and review of claims submitted to Federal health care programs for arterial and
vascular procedures. If Qamar terminates the ICC during the course of the engagement, Qamar must submit a notice explaining his reasons to OIG no later than 30 days after termination and Qamar must engage a new ICC in accordance with this paragraph III.B.

C. Training and Education

1. Training. Practitioner and all other Covered Persons shall receive at least three hours of training during the first Reporting Period. Training may be completed in-person or online. These training requirements may be satisfied only by the completion of courses provided by the Centers for Medicare & Medicaid Services (CMS) Medicare Learning Network (MLN), Qamar’s Medicare contractor, or other training courses that are submitted to OIG, prior to registration for the training course, for review and approval.

At a minimum, the required training sessions must include the following topics:

   a. the Federal health care program billing, coding and claim submission statutes, regulations, and program requirements and directives relating to the items or services furnished by Qamar; and

   b. the Federal health care program medical record documentation requirements relating to items or services furnished by Qamar.

New Covered Persons shall receive at least three hours of training within 90 days after becoming a Covered Person.

The OIG may, in its discretion, require that Qamar and other Covered Persons complete additional hours of training regarding the topics identified above, or additional topics, in the second and third years of the IA. The OIG shall provide notice to Qamar of such additional required training at least 180 days prior to the required completion date for such training.

2. Training Records. Qamar shall maintain written documentation (e.g., written or electronic certificates of completion from the training provider) that all Covered Persons required to receive training have in fact completed such training. The documentation shall specify the type of training received, the individual who completed the training, and the date received.
D. Review Procedures

1. General Description.

   a. Engagement of Independent Review Organization. Within 60 days after the Effective Date, Qamar shall engage an individual or entity, such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform the reviews listed in this Section III.C. The applicable requirements relating to the IRO are outlined in Appendix A to this IA, which is incorporated by reference.

   b. Retention of Records. The IRO and Qamar shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and Qamar) related to the reviews.

2. Claims Review. The IRO shall conduct a review of Qamar’s claims submitted to and reimbursed by the Medicare and Medicaid programs, to determine whether the items and services furnished were medically necessary and appropriately documented, and whether the claims were correctly coded, submitted, and reimbursed for each three-month period during the term of this IA (Quarterly Claims Review) and shall prepare a Quarterly Claims Review Report, as outlined in Appendix B to this IA, which is incorporated by reference. The first three-month period for purposes of the Quarterly Claims Review requirement shall begin 30 days after the Effective Date. Each Quarterly Claims Review Report shall be submitted to OIG within 60 days following the end of the three-month period covered by the Quarterly Claims Review.

3. Arterial and Vascular Procedures Review. The IRO shall evaluate and analyze the medical necessity and appropriateness of arterial and vascular procedures performed by Qamar for each three-month period during the term of this IA (Quarterly Arterial and Vascular Procedures Review). In conducting the Quarterly Arterial and Vascular Procedures Review, the IRO shall consult with the Independent Cardiology Consultant. In conducting the Quarterly Arterial and Vascular Procedures Review, the IRO shall review the arterial and vascular procedures for appropriateness of case selection, quality of procedures, execution, proper response to intraprocedural problems,
accurate assessment of procedure outcome, and appropriateness of procedure management. The procedures shall be reviewed based on the supporting documentation available from Qamar or under Qamar’s control and applicable regulations and guidance, including but not limited to the established practice guidelines and generally accepted standards of practice described by the American College of Cardiology, to determine whether the procedures were medically necessary and appropriate. The IRO shall prepare an Arterial and Vascular Procedures Review Report, as outlined in Appendix B to this IA, which is incorporated by reference. The first three-month period for purposes of the Quarterly Arterial and Vascular Procedures Review requirement shall begin 30 days after the Effective Date. Each Quarterly Arterial and Vascular Procedures Review Report shall be submitted to OIG within 60 days following the end of the three-month period covered by the Quarterly Arterial and Vascular Procedures Review.

4. Independence and Objectivity Certification. Prior to performing the first Quarterly Arterial and Vascular Procedures Review, and annually thereafter, the IRO shall provide to Qamar a certification that the IRO has (a) evaluated its professional independence and objectivity with respect to the reviews required under this Section III.C and (b) concluded that it is, in fact, independent and objective, in accordance with the requirements specified in Appendix A to this IA. The IRO’s certification shall include a summary of all current and prior engagements between Qamar and the IRO.

E. Ineligible Persons

1. Definitions. For purposes of this IA:

   a. an “Ineligible Person” shall include an individual or entity who:

      i. is currently excluded from participation in any Federal health care program; or

      ii. has been convicted of (a) a criminal offense that is related to the delivery of an item or service under Medicare or any state health care program; (b) a criminal offense relating to neglect or abuse of patients; (c) a felony criminal offense relating to fraud, theft, embezzlement, breach of fiduciary responsibility, or other financial misconduct in connection with the delivery of a health care item or service.
service or with respect to a government funded health care program (other than Medicare or a state health care program); or (d) a felony criminal offense relating to the unlawful manufacture, distribution, prescription or dispensing of a controlled substance, but has not yet been excluded, debarred, suspended, or otherwise declared ineligible.


2. **Screening Requirements.** Qamar shall ensure that all prospective and current Covered Persons are not Ineligible Persons, by implementing the following screening requirements.

a. Qamar shall screen all prospective Covered Persons against the Exclusion List prior to engaging their services and, as part of the hiring or contracting process, shall require such Covered Persons to disclose whether they are Ineligible Persons.

b. Qamar shall screen all current Covered Persons against the Exclusion List within 30 days after the Effective Date and on a monthly basis thereafter.

c. Qamar shall require all Covered Persons to disclose immediately if they become an Ineligible Person.

Qamar shall maintain documentation demonstrating that Qamar: (1) has checked the Exclusion List (e.g., print screens from search results) and determined that its Covered Persons are not Ineligible Persons; and (2) has required its Covered Persons to disclose if they are an Ineligible Person.

Nothing in this Section III.D affects Qamar’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by an excluded person. Qamar understands that items or services furnished by excluded persons are not payable by Federal health care programs and that Qamar may be liable for overpayments and/or criminal, civil, and administrative sanctions for
employing or contracting with an excluded person regardless of whether Qamar meets the requirements of Section III.D.

3. **Removal Requirement.** If Qamar has actual notice that a Covered Person has become an Ineligible Person, Qamar shall remove such Covered Person from responsibility for, or involvement with, Qamar’s business operations related to the Federal health care program(s) from which such Covered Person has been excluded and shall remove such Covered Person from any position for which the Covered Person’s compensation or the items or services furnished, ordered, or prescribed by the Covered Person are paid in whole or part, directly or indirectly, by any Federal health care program(s) from which the Covered Person has been excluded at least until such time as the Covered Person is reinstated into participation in such Federal health care program(s).

4. **Pending Charges and Proposed Exclusions.** If Qamar has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term, Qamar shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary or the accuracy of any claims submitted to any Federal health care program.

F. **Notification of Government Investigation or Legal Proceeding**

Within 30 days after discovery, Qamar shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Qamar conducted or brought by a governmental entity or its agents involving an allegation that Qamar has committed a crime or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Qamar shall also provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the investigation or proceeding, if any.

G. **Overpayments**

1. **Definition of Overpayments.** For purposes of this IA, an “Overpayment” shall mean the amount of money Qamar has received in excess of the amount due and payable under any Federal health care program requirements.
2. **Repayment of Overpayments.** If, at any time, Qamar identifies any Overpayment, Qamar shall repay the Overpayment to the appropriate payor (e.g., Medicare contractor) in accordance with the requirements of the Centers for Medicare and Medicaid Services (CMS) overpayment statute and regulations, 42 U.S.C. § 1320a-7k(d) and 42 C.F.R. §§ 401.301-305, and any applicable CMS guidance. Qamar should follow the payor’s policies regarding the form of notification and the repayment process for any Overpayment refunds. Any questions regarding the repayment process should be directed to the payor.

H. **Reportable Events**

1. **Definition of Reportable Event.** For purposes of this IA, a “Reportable Event” means anything that involves:

   a. a substantial Overpayment;

   b. a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;

   c. the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.D.1.a; or

   d. the filing of a bankruptcy petition by Qamar.

A Reportable Event may be the result of an isolated event or a series of occurrences.

2. **Reporting of Reportable Events.** If Qamar determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Qamar shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists.

3. **Reportable Events under Section III.G.1.a and III.G.1.b.** For Reportable Events under Section III.G.1.a and b, the report to OIG shall include:

   a. a complete description of all details relevant to the Reportable Event, including, at a minimum, the types of claims,
transactions or other conduct giving rise to the Reportable Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;

b. a statement of the Federal criminal, civil or administrative laws that are probably violated by the Reportable Event, if any;

b. the Federal health care programs affected by the Reportable Event;

c. a description of the steps taken by Qamar to identify and quantify any Overpayments; and

d. a description of Qamar’s actions taken to correct the Reportable Event and prevent it from recurring.

If the Reportable Event involves an Overpayment, Qamar shall send to OIG a copy of the notification and repayment (if quantified) to the payor.

4. Reportable Events under Section III.G.1.c. For Reportable Events under Section III.G.1.c, the report to OIG shall include:

a. the identity of the Ineligible Person and the job duties performed by that individual;

b. the dates of the Ineligible Persons employment or contractual relationship;

c. a description of the Exclusion List screening that Qamar completed before and/or during the Ineligible Person’s employment or contract and any flaw or breakdown in the screening process that led to the hiring or contracting with the Ineligible Person;

d. a description of how the Ineligible Person was identified; and
e. a description of any corrective action implemented to prevent future employment or contracting with an Ineligible Person.

5. Reportable Events under Section III.G.1.d. If the Reportable Event involves the filing of a bankruptcy petition, the report to the OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program requirements implicated.

6. Reportable Events Involving the Stark Law. Notwithstanding the reporting requirements outlined above, any Reportable Event that involves solely a probable violation of section 1877 of the Social Security Act, 42 U.S.C. §1395nn (the Stark law) should be submitted by Qamar to CMS through the self-referral disclosure protocol (SRDP), with a copy to the OIG. If Qamar identifies a probable violation of the Stark law and repays the applicable Overpayment directly to the CMS contractor, then Qamar is not required by this Section III.F to submit the Reportable Event to CMS through the SRDP.

I. Third Party Billing

If, prior to the Effective Date or at any time during the term of this IA Qamar contracts with a third party billing company to submit claims to the Federal health care programs on behalf of Qamar, Qamar must certify to OIG that he does not have an ownership or control interest (as defined in 42 U.S.C. § 1320a-3(a)(3)) in the third party billing company and is not employed by, and does not act as a consultant to, the third party billing company.

Qamar also shall obtain (as applicable) a certification from any third party billing company that the company: (i) has a policy of not employing any person who is excluded from participation in any Federal health care program to perform any duties related directly or indirectly to the preparation or submission of claims to Federal health care programs; (ii) screens its prospective and current employees against the Exclusion List; and (iii) provides training in the applicable requirements of the Federal health care programs to those employees involved in the preparation and submission of claims to Federal health care programs.

If applicable, a copy of these certifications shall be included in Qamar’s Implementation Report and each Annual Report required by Section V below.
IV. SUCCESSOR LIABILITY; CHANGES TO LOCATIONS OR BUSINESS; NEW EMPLOYMENT OR CONTRACTUAL ARRANGEMENT

A. Sales or Purchase of a Location or Business In the event that, after the Effective Date, Qamar proposes to (a) sell any or all of its locations or businesses that are subject to this IA (whether through a sale of assets, a sale of stock, or other type of transaction), or (b) purchase or establish a new location or business related to the furnishing of items or services that may be reimbursed by any Federal health care program, the IA shall be binding on the purchaser of any such location or business and any new location or business (and all Covered Persons at each new location or business) shall be subject to the requirements of this IA, unless otherwise determined and agreed to in writing by OIG.

If, in advance of a proposed sale or proposed purchase, Qamar wishes to obtain a determination by OIG that the proposed purchaser or the proposed acquisition will not be subject to the requirements of the IA, Qamar must notify OIG in writing of the proposed sale or purchase at least 30 days in advance. This notification shall include a description of the location or business to be sold or purchased, a brief description of the terms of the transaction and, in the case of a proposed sale, the name and contact information of the proposed purchaser.

B. New Employment or Contractual Arrangement

At least 30 days prior to Qamar becoming an employee or contractor with another party related to the furnishing of items or services that may be reimbursed by any Federal health care program, Qamar shall notify OIG of his plan to become an employee or contractor and must provide OIG with the name, location, status (employee or contractor) and an explanation of Qamar’s responsibilities with respect to such potential employer or contractor. In addition, prior to Qamar becoming an employee or contractor with another party related to the furnishing of items or services that may be reimbursed by any Federal health care program, Qamar shall notify that party of this IA. This notification shall include a copy of the IA and a statement indicating the remaining term of the IA. The IA shall continue to apply to Qamar following the start of the new employment or contractual relationship, unless otherwise agreed to in writing by the OIG.

V. IMPLEMENTATION REPORT, IRO REPORTS AND ANNUAL REPORTS

A. Implementation Report
Within 90 days after the Effective Date, Qamar shall submit a written report to OIG summarizing the status of its implementation of the requirements of this IA (Implementation Report). The Implementation Report shall, at a minimum, include:

1. a copy of the notice required by Section III.A, a description of where the notice is posted, and the date the notice was posted;

2. the following information regarding the IRO: (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this IA; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to Qamar;

3. a copy of the documentation demonstrating that Qamar has screened all Covered Persons against the Exclusion List, as required by section III.D, within 30 days of the Effective Date;

4. a copy of any certifications from Qamar and the third party billing company required by Section III.H (if applicable);

5. a list of all of Qamar’s locations (including locations and mailing addresses), the corresponding name under which each location is doing business, and each location’s Medicare and state Medicaid program provider number(s), and/or supplier number(s); and

6. a certification by Qamar that: (a) he or she has reviewed the IA in its entirety, understands the requirements described within, and maintains a copy for reference; (b) to the best of his or her knowledge, except as otherwise described in the Implementation Report, Qamar is in compliance with all of the requirements of this IA; and (c) he or she has reviewed the Implementation Report and has made a reasonable inquiry regarding its content and believes that the information is accurate and truthful.

B. IRO Reports

Within 60 days following the end of each three-month period during the term of this IA, Qamar shall provide to OIG a copy of the Quarterly Claims Review Report prepared by the IRO for each Quarterly Claims Review performed, as well as a copy of
the Quarterly Arterial and Vascular Procedures Review along with Qamar’s response and corrective action plan related to any recommendations made by the IRO in the Quarterly Claims Review Report and the Quarterly Arterial and Vascular Procedures Review. Each Quarterly Claims Review Report and Quarterly Arterial and Vascular Procedures Review shall include the information specified in Appendix B to this IA.

C. Annual Reports

Qamar shall submit to OIG a report on its compliance with the IA requirements for each of the three Reporting Periods (Annual Report). Each Annual Report shall, at a minimum, include:

1. (in the first Annual Report) the following information regarding the training required by Section III.B during the first reporting period (and any additional hours of training required for the second and third reporting periods): a copy of the training program registration for each Covered Person who completed the training, the name of the training course, the name of the entity that provided the training, the location, date and length of the training; and a training program brochure or other materials from the training program or training program sponsor that describe the content of the training program. A copy of all training materials shall be made available to OIG upon request;

2. a certification from the IRO regarding its professional independence and objectivity with respect to Qamar;

3. a copy of the documentation demonstrating that Qamar screened all prospective and current Covered Persons against the Exclusion List, as required by Section III.D;

4. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.E. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

5. a report of the aggregate Overpayments that have been returned to the Federal health care programs during the Reporting Period. Overpayment amounts shall be broken down into the following categories: Medicare, Medicaid, and other Federal health care programs;
6. a summary of Reportable Events (as defined in Section III.G) identified during the Reporting Period;

7. a copy of any certifications from Qamar and the third party billing company required by Section III.H (if applicable);

8. a summary of any audits conducted during the applicable Reporting Period by any Medicare or state Medicaid program contractor or other government entity or contractor, involving a review of Federal health care program claims, and Qamar’s response/corrective action plan (including information regarding any Federal health care program refunds) relating to the audit findings;

9. a description of all changes to the most recently provided list of Qamar’s locations (including addresses) as required by Section V.A.5; and

10. a certification signed by Qamar that: (a) he or she has reviewed the IA in its entirety, understands the requirements described within, and maintains a copy for reference; (b) to the best of his or her knowledge, except as otherwise described in the Annual Report, Qamar is in compliance with all of the requirements of this IA; and (c) he or she has reviewed the Annual Report and has made a reasonable inquiry regarding its content and believes that the information is accurate and truthful.

The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.

D. Designation of Information

Qamar shall clearly identify any portions of its submissions that [he, she or it] believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Qamar shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

VI. NOTIFICATIONS AND SUBMISSION OF REPORTS

Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this IA shall be submitted to the following entities:
OIG:
Administrative and Civil Remedies Branch
Office of Counsel to the Inspector General
Office of Inspector General
U.S. Department of Health and Human Services
Cohen Building, Room 5527
330 Independence Avenue, SW
Washington, DC 20201
Telephone:  (202) 619-2078
Facsimile: (202) 205-0604

Qamar:

Name:  Asad Qamar
Address: 4730 SW 49th Rd, Ocala, FL 34474
Telephone: 352-804-4049
Email: heartdoc40@hotmail.com

Unless otherwise specified, all notifications and reports required by this IA shall be made by electronic mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. Upon request by OIG, Qamar may be required to provide OIG with an electronic copy of each notification or report required by this IA, in addition to a paper copy.

VII. OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may conduct interviews, examine or request copies of Qamar’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Qamar’s locations for the purpose of verifying and evaluating: (a) Qamar’s compliance with the terms of this IA and (b) Qamar’s compliance with the requirements of the Federal health care programs. The documentation described above shall be made available by Qamar to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, and/or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview Qamar and any of Qamar’s employees or contractors who consent to be interviewed at the individual’s place of business during normal
business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Qamar shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Qamar’s employees and contractors may elect to be interviewed with or without a representative of Qamar present.

VIII. DOCUMENT AND RECORD RETENTION

Qamar shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this IA for four years (or longer if otherwise required by law) from the Effective Date.

IX. DISCLOSURES

Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Qamar prior to any release by OIG of information submitted by Qamar pursuant to its obligations under this IA and identified upon submission by Qamar as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Qamar shall have the rights set forth at 45 C.F.R. § 5.65(d).

X. BREACH AND DEFAULT PROVISIONS

Qamar is expected to fully and timely comply with all of his IA obligations.

A. Stipulated Penalties for Failure to Comply with Certain Obligations

As a contractual remedy, Qamar and OIG hereby agree that failure to comply with certain obligations set forth in this IA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions.

1. A Stipulated Penalty of $1,000 (which shall begin to accrue on the day after the date the obligation became due) for each day Qamar fails to:

a. post a notice in accordance with the requirements of Section III.A;
b. complete the training required for Qamar and Covered Persons and maintain training records, in accordance with the requirements of Section III.B;

c. screen Covered Persons in accordance with the requirements of Section III.D; or require Covered Persons to disclose if they are excluded in accordance with the requirements of Section III.D; and maintain documentation of screening and disclosure requirements in accordance with the requirements of Section III.D;

d. notify OIG of a government investigation or legal proceeding, in accordance with the requirements of Section III.E;

e. repay any Overpayments as required by Section III.F and Appendix B; or

f. report a Reportable Event in accordance with Section III.G.

g. engage and use an ICC in accordance with the requirements of Section III.B;

h. provide to OIG the certifications required by Section III.H relating to any third party biller engaged by Qamar during the term of the IA.
and Appendix B or fails to repay any Overpayment identified by the IRO, as required by Appendix B.

5. A Stipulated Penalty of $1,000 for each day Qamar fails to grant access as required in Section VII. (This Stipulated Penalty shall begin to accrue on the date Qamar fails to grant access.)

6. A Stipulated Penalty of $50,000 for each false certification submitted by or on behalf of Qamar as part of its Implementation Report, any Annual Report, additional documentation to a report (as requested by OIG), or as otherwise required by this IA.

7. A Stipulated Penalty of $1,000 for each day Qamar fails to comply fully and adequately with any obligation of this IA. OIG shall provide notice to Qamar stating the specific grounds for its determination that Qamar has failed to comply fully and adequately with the IA obligation(s) at issue and steps the Qamar shall take to comply with the IA. (This Stipulated Penalty shall begin to accrue 10 days after the date Qamar receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1-6 of this Section.

B. Timely Written Requests for Extensions

Qamar may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this IA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Qamar fails to meet the revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three business days after Qamar receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five days prior to the date by which any act is due to be performed or any notification or report is due to be filed.

C. Payment of Stipulated Penalties
1. **Demand Letter.** Upon a finding that Qamar has failed to comply with any of the obligations described in Section X.A and after determining that Stipulated Penalties are appropriate, OIG shall notify Qamar of: (a) Qamar’s failure to comply; and (b) OIG’s exercise of its contractual right to demand payment of the Stipulated Penalties. (This notification shall be referred to as the “Demand Letter.”)

2. **Response to Demand Letter.** Within 10 days after the receipt of the Demand Letter, Qamar shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties; or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Qamar elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Qamar cures, to OIG’s satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this IA and shall be grounds for exclusion under Section X.D.

3. **Form of Payment.** Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand Letter.

4. **Independence from Material Breach Determination.** Except as set forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Qamar has materially breached this IA, which decision shall be made at OIG’s discretion and shall be governed by the provisions in Section X.D, below.

D. **Exclusion for Material Breach of this IA**

1. **Definition of Material Breach.** A material breach of this IA means:

   a. a failure by Qamar to report a Reportable Event, take corrective action, or make the appropriate refunds, as required in Section III.G;

   b. repeated violations or a flagrant violation of any of the obligations under this IA, including, but not limited to, the obligations addressed in Section X.A;

Dr. Asad Qamar Integrity Agreement
June 2016
2. **Notice of Material Breach and Intent to Exclude.** The parties agree that a material breach of this IA by Qamar constitutes an independent basis for Qamar’s exclusion from participation in the Federal health care programs. The length of the exclusion shall be in the OIG’s discretion, but not more than three years per material breach. Upon a determination by OIG that Qamar has materially breached this IA and that exclusion is the appropriate remedy, OIG shall notify Qamar of: (a) Qamar’s material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion. (This notification shall be referred to as the “Notice of Material Breach and Intent to Exclude.”)

3. **Opportunity to Cure.** Qamar shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate that:

   a. the alleged material breach has been cured; or

   b. the alleged material breach cannot be cured within the 30 day period, but that: (i) Qamar has begun to take action to cure the material breach; (ii) Qamar is pursuing such action with due diligence; and (iii) Qamar has provided to OIG a reasonable timetable for curing the material breach.

4. **Exclusion Letter.** If, at the conclusion of the 30 day period, Qamar fails to satisfy the requirements of Section X.D.3, OIG may exclude Qamar from participation in the Federal health care programs. OIG shall notify Qamar in writing of its determination to exclude Qamar. (This letter shall be referred to as the “Exclusion Letter.”) Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of Qamar’s receipt of the Exclusion Letter. The exclusion shall have national effect. Reinstatement to program participation is not automatic. At the end of the period of exclusion, Qamar may apply for reinstatement, by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004.
E. **Dispute Resolution**

1. **Review Rights.** Upon OIG’s delivery to Qamar of its Demand Letter or of its Exclusion Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this IA, Qamar shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or exclusion sought pursuant to this IA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. The procedures relating to the filing of a request for a hearing can be found at http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html.

2. **Stipulated Penalties Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this IA shall be: (a) whether Qamar was in full and timely compliance with the obligations of this IA for which OIG demands payment; and (b) the period of noncompliance. Qamar shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this IA and orders Qamar to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless Qamar requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision.

3. **Exclusion Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this IA shall be whether Qamar was in material breach of this IA and, if so, whether:

   a. Qamar cured such breach within 30 days of its receipt of the Notice of Material Breach; or
b. the alleged material breach could not have been cured within the 30 day period, but that, during the 30 day period following Qamar’s receipt of the Notice of Material Breach: (i) Qamar had begun to take action to cure the material breach; (ii) Qamar pursued such action with due diligence; and (iii) Qamar provided to OIG a reasonable timetable for curing the material breach.

For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for Qamar, only after a DAB decision in favor of OIG. Qamar’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude Qamar upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Qamar may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Qamar shall waive [his/her] right to any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Qamar, Qamar shall be reinstated effective on the date of the original exclusion.

4. Finality of Decision. The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. Consequently, the parties to this IA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this IA.

XI. EFFECTIVE AND BINDING AGREEMENT

Qamar and OIG agree as follows:

A. This IA shall become final and binding on the date the final signature is obtained on the IA.

B. This IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this IA.

C. OIG may agree to a suspension of Qamar’s obligations under this IA based on a certification by Qamar that he is no longer providing health care items or services
that will be billed to any Federal health care program and he does not have any ownership or control interest, as defined in 42 U.S.C. §1320a-3, in any entity that bills any Federal health care program. If Qamar is relieved of his IA obligations, Qamar shall be required to notify OIG in writing at least 30 days in advance if Qamar plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the IA will be reactivated or modified.

D. All requirements and remedies set forth in this IA are in addition to and do not affect: (1) Qamar’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.

E. The undersigned Qamar signatory represents and warrants that [he/she] is authorized to execute this IA. The undersigned OIG signatories represent that they are signing this IA in their official capacity and that they are authorized to execute this IA.

F. This IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same IA. Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this IA.
ON BEHALF OF Qamar

/Asad U. Qamar/   6/22/16
Asad U. Qamar, M.D.   DATE

/Aaron Wernick/   6/23/16
Counsel   DATE
ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

/Robert K. DeConti/   6/24/16
ROBERT K. DECONTI      DATE
Assistant Inspector General for Legal Affairs
Office of Inspector General
U. S. Department of Health and Human Services

/Nancy W. Brown/   6/24/16
NANCY W. BROWN      DATE
Senior Counsel
Office of Inspector General
U. S. Department of Health and Human Services
APPENDIX A

INDEPENDENT REVIEW ORGANIZATION

This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.C of the IA.

A. IRO Engagement

1. Qamar shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.2 of the IA or any additional information submitted by Qamar in response to a request by OIG, whichever is later, OIG will notify Qamar if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Qamar may continue to engage the IRO.

2. If Qamar engages a new IRO during the term of the IA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Qamar shall submit the information identified in Section V.A.2 of the IA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information, or any additional information submitted by Qamar at the request of OIG, whichever is later, OIG will notify Qamar if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Qamar may continue to engage the IRO.

B. IRO Qualifications

The IRO shall:

1. assign individuals to conduct the Quarterly Claims Review who have expertise in the billing, coding, claims submission, and other Federal health care program requirements relating to claims submitted by or on behalf of Qamar for cardiology items and services provided by Qamar.

2. assign individuals to conduct the Arterial and Vascular Procedures Review who are certified by the American Board of Internal Medicine in Cardiology, have expertise in interventional cardiology and in the billing, coding, claims submission, and other Federal health care program reimbursement requirements for cardiology services;
3. assign individuals to design and select the Quarterly Claims Review sample and the Arterial and Vascular Procedures Review who are knowledgeable about the appropriate statistical sampling techniques;

4. assign individuals to conduct the coding review portions of the Quarterly Claims Review who have a nationally recognized coding certification and who have maintained this certification (e.g., completed applicable continuing education requirements); and

5. have sufficient staff and resources to conduct the reviews required by the IA on a timely basis.

C. IRO Responsibilities

The IRO shall:

1. perform each Quarterly Claims Review and each Arterial and Vascular Procedures Review in accordance with the specific requirements of the IA;

2. follow all applicable Medicare and state Medicaid program rules and reimbursement guidelines in making assessments in the Claims Review and the Arterial and Vascular Procedures Review;

3. request clarification from the appropriate authority (e.g., Medicare contractor), if in doubt of the application of a particular Medicare or state Medicaid program policy or regulation;

4. respond to all OIG inquires in a prompt, objective, and factual manner; and

5. prepare timely, clear, well-written reports that include all the information required by Appendix B to the IA.

D. IRO Independence and Objectivity

The IRO must perform each Quarterly Claims Review and the Arterial and Vascular Procedures Review in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the U.S. Government Accountability Office.

E. IRO Removal/Termination

1. *Qamar and IRO.* If Qamar terminates its IRO or if the IRO withdraws from the engagement during the term of the IA, Qamar must submit a notice explaining
(a) its reasons for termination of the IRO or (b) the IRO’s reasons for its withdrawal to OIG no later than 30 days after termination or withdrawal. Qamar must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the IRO.

2. **OIG Removal of IRO.** In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG shall notify Qamar in writing regarding OIG’s basis for determining that the IRO has not met the requirements of this Appendix. Qamar shall have 30 days from the date of OIG’s written notice to provide information regarding the IRO’s qualifications, independence or performance of its responsibilities in order to resolve the concerns identified by OIG. If, following OIG’s review of any information provided by Qamar regarding its IRO, OIG determines that the IRO has not met the requirements of this Appendix, OIG shall notify Qamar in writing that Qamar shall be required to engage a new IRO in accordance with Paragraph A of this Appendix. Qamar must engage a new IRO within 60 days of receipt of OIG’s written notice. The final determination as to whether or not to require Qamar to engage a new IRO shall be made at the sole discretion of OIG.
APPENDIX B

CLAIMS AND ARTERIAL AND VASCULAR PROCEDURES REVIEW

A. Quarterly Claims Review. The IRO shall conduct a review of Qamar’s claims submitted to and reimbursed by the Medicare and Medicaid programs, to determine whether the items and services furnished were medically necessary and appropriately documented, and whether the claims were correctly coded, billed, and reimbursed, for each three-month period during the term of this IA (Quarterly Claims Review) and prepare a report for each Quarterly Claims Review performed. The first three-month period shall begin 30 days following the Effective Date of this IA.

1. Definitions. For the purposes of this Appendix B, the following definitions shall be used:

a. Overpayment: The amount of money Qamar has received in excess of the amount due and payable under Medicare or any state Medicaid program requirements, as determined by the IRO in connection with the claims reviews performed under this Appendix B, including any extrapolated Overpayments determined in accordance with Section A.2.e of this Appendix B.

b. Paid Claim: A claim submitted by Qamar and for which Qamar has received reimbursement from the Medicare program or a state Medicaid program.

c. Population: The Population shall be defined as all Paid Claims during the three-month period covered by the Quarterly Claims Review.

2. Quarterly Claims Sample.

a. Within 15 days following the end of each three-month period during the term of the IA, the IRO shall randomly select a sample of 30 Paid Claims submitted by or on behalf of Qamar during the preceding three-month period (Quarterly Claims Sample). The sample must be selected through the use of OIG’s Office of Audit Services’ Statistical Sampling Software, also known as RAT-STATS, which is currently available at https://oig.hhs.gov/compliance/rat-stats/index.asp.

b. Qamar shall provide the IRO with a list of all Qamar’s Paid Claims for the three-month period covered by the Quarterly Claims Sample.
The IRO should number each Paid Claim in the Population sequentially prior to generating the random numbers used to select the Quarterly Claims Sample. The IRO should generate 30 random numbers using RAT-STATS and then use the random numbers to identify the 30 Paid Claims in the Population that will be subject to review by the IRO.

c. The randomly selected 30 Paid Claims shall be reviewed by the IRO based on the supporting documentation available at Qamar’s office or under Qamar’s control and applicable Medicare and state Medicaid program requirements to determine whether the items and services furnished were medically necessary and appropriately documented, and whether the claim was correctly coded, submitted, and reimbursed.

d. The IRO shall prepare a written report of its findings from the Quarterly Claims Sample, as described in Section C below (Quarterly Claims Review Report). The Quarterly Claims Review Report shall be submitted to the OIG within 60 days following the end of the three-month period covered by each Quarterly Claims Review.

e. The findings of the Quarterly Claims Sample shall be used by the IRO to estimate the actual Overpayment in the Population at the mean point estimate.

3. **Repayment of Identified Overpayments.** Qamar shall repay within 60 days any Overpayments identified in the Quarterly Claims Sample, as determined by the IRO under Section A.2.e above, in accordance with the requirements of 42 U.S.C. § 1320a-7k(d) and 42 C.F.R. §§ 401.301-305 (and any applicable CMS guidance). Qamar shall make available to OIG all documentation that reflects the refund of the Overpayment(s) to the payor. OIG, in its sole discretion, may refer the findings of the Quarterly Claims Review Sample (and any related work papers) received from Qamar to the appropriate Medicare or state Medicaid program contractor for appropriate follow up by that payor.

1. **Claims Review Methodology.**

   a. **Claims Review Population.** A description of the Population subject to the Quarterly Claims Review.

   b. **Source of Data.** A description of (1) the process used to identify claims in the Population, and (2) the specific documentation relied upon by the IRO when performing the Quarterly Claims Review (e.g., medical records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare contractor manual or bulletins (including issue and date), other policies, regulations, or directives).

   c. **Review Protocol.** A narrative description of how the Quarterly Claims Review was conducted and what was evaluated.

   d. **Supplemental Materials.** The IRO shall request all documentation and materials required for its review of the Paid Claims selected as part of each Quarterly Claims Sample and Qamar shall furnish such documentation and materials to the IRO, prior to the IRO initiating its review of the Quarterly Claims Sample. If the IRO accepts any supplemental documentation or materials from Qamar after the IRO has completed its initial review of the Quarterly Claims Sample (Supplemental Materials), the IRO shall identify in the Quarterly Claims Review Report the Supplemental Materials, the date the Supplemental Materials were accepted, and the relative weight the IRO gave to the Supplemental Materials in its review. In addition, the IRO shall include a narrative in the Quarterly Claims Review Report describing the process by which the Supplemental Materials were accepted and the IRO’s reasons for accepting the Supplemental Materials.

2. **Statistical Sampling Documentation.** A copy of the printout of the random numbers generated by the “Random Numbers” function of RAT-STATS used by the IRO to select the Quarterly Claims Sample.
3. **Claims Review Findings.**

a. **Narrative Results.**

i. For the first Quarterly Claims Review Report only, a description of (a) Qamar’s billing and coding system(s), including the identification, by position description, of the personnel involved in coding and billing, and (b) a description of controls in place to ensure that all items and services billed to Medicare or a state Medicaid program by Qamar are medically necessary and appropriately documented. Subsequent Quarterly Claims Review Reports should describe any significant changes to items (a) and (b) or, if no significant changes were made, state that the systems and controls remain the same as described in the prior Quarterly Claims Review Report.

ii. A narrative explanation of the results of the Quarterly Claims Sample, including reasons for errors, patterns noted, etc.

b. **Quantitative Results.**

i. Total number and percentage of instances in which the IRO determined that the coding of the Paid Claims submitted by Qamar differed from what should have been the correct coding and in which such difference resulted in an Overpayment to Qamar.

ii. Total number and percentage of instances in which the IRO determined that a Paid Claim was not appropriately documented and in which such documentation errors resulted in an Overpayment to Qamar.

iii. Total number and percentage of instances in which the IRO determined that a Paid Claim was for items or services that were not medically necessary and resulted in an Overpayment to Qamar.

iv. Total dollar amount of all Overpayments in the Quarterly Claims Review Sample.

v. Total dollar amount of Paid Claims included in the Quarterly Claims Review Sample.
vi. Error Rate in the Quarterly Claims Review Sample. The Error Rate shall be calculated by dividing the Overpayment in the Quarterly Claims Review Sample by the total dollar amount associated with the Paid Claims in the Quarterly Claims Review Sample.

vii. A spreadsheet of the Quarterly Claims Sample results that includes the following information for each Paid Claim: Federal health care program billed, beneficiary health insurance claim number, date of service, procedure code submitted, procedure code reimbursed, allowed amount reimbursed by payor, correct procedure code (as determined by the IRO), correct allowed amount (as determined by the IRO), dollar difference between allowed amount reimbursed by payor and the correct allowed amount.

c. Recommendations. The IRO’s report shall include any recommendations for improvements to Qamar’s billing and coding system or to Qamar’s controls for ensuring that all items and services billed to Medicare or a state Medicaid program are medically necessary and appropriately documented, based on the findings of the Quarterly Claims Review.

d. Credentials. The names and credentials of the individuals who: (1) designed the review methodology utilized for the Quarterly Claims Review and (2) performed the Quarterly Claims Review.

C. Arterial and Vascular Procedures Review.

The IRO shall conduct a review of arterial and vascular procedures performed by Qamar, for each three-month period during the term of this IA (Quarterly Arterial and Vascular Procedures Review). In conducting the Quarterly Arterial and Vascular Procedures Reviews, the IRO shall consult with the Independent Cardiology Consultant. The IRO shall prepare a report for each Arterial and Vascular Procedures Review performed. The first three-month period shall begin 30 days following the Effective Date of this IA.

Definitions. For the purposes of the Arterial and Vascular Procedures Review, the following definitions shall be used:
a. **Arterial and Vascular Procedure.** Arterial and Vascular procedures (including catheterization, angiographies, ultrasounds, stents, angioplasties) performed by Qamar.

b. **Population.** For each Reporting Period, the Population shall be defined as all Arterial and Vascular procedures performed by Qamar for which Qamar has received reimbursement from Medicare, Medicaid, or other Federal health care programs during the three-month period covered by the Quarterly Arterial and Vascular Review.

F. **Quarterly Arterial and Vascular Procedures Sample.** Within 15 days following the end of each three-month period during the term of this IA, the IRO shall randomly select a sample of 30 Arterial and Vascular Procedures performed by Qamar during the preceding three-month period (Quarterly Arterial and Vascular Procedures Sample). The sample must be selected through the use of OIG’s Office of Audit Services’ Statistical Sampling Software, also known as RAT-STATS, which is currently available at [https://oig.hhs.gov/compliance/rat-stats/index.asp](https://oig.hhs.gov/compliance/rat-stats/index.asp). Qamar shall provide the IRO with a list of all Qamar’s Paid Claims for the three-month period covered by the Quarterly Arterial and Vascular Procedures review. The IRO should number each Arterial and Vascular Procedure in the Population sequentially prior to generating the random numbers used to select the Quarterly Arterial and Vascular Procedures Sample. The IRO should generate 30 random numbers using RAT-STATS and then use the random numbers to identify the 30 Arterial and Vascular Procedures in the Population that will be subject to review by the IRO. The randomly selected 30 Arterial and Vascular Procedures will be reviewed by the IRO based on the supporting documentation available at Qamar’s office or under Qamar’s control and applicable billing and coding regulations and guidance to determine whether each procedure was medically necessary or appropriate, based on established practice guidelines and generally accepted standards of medical practice as described by the American College of Cardiology. The IRO shall prepare a written report of its findings from the Quarterly Arterial and Vascular Procedures Sample, as described in Section G below (Quarterly Arterial and Vascular Procedures Review Report). The Quarterly Arterial and Vascular Procedures Review Report shall be submitted to the OIG within 60 days following the end of the three-month period covered by each Quarterly Arterial and Vascular Procedures Review.

G. **Arterial and Vascular Procedures Review Report.** The following information shall be included in the Arterial and Vascular Procedures Review for each Sample.

1. **Arterial and Vascular Procedures Review Methodology.**

   a. **Sampling Unit.** A description of the Arterial and Vascular
Procedures as that term is defined above.


c. **Arterial and Vascular Procedures Review Objective.** A clear statement of the objective intended to be achieved by the Arterial and Vascular Procedures Review.

d. **Sampling Frame.** A description of the sampling frame, which is the totality of Arterial and Vascular Procedures from which the Sample has been selected and an explanation of the methodology used to identify the sampling frame. In most circumstances the sampling frame will be identical to the Population.

e. **Source of Data.** A description of the specific documentation relied upon by the IRO when performing the Arterial and Vascular Procedures Review (e.g., medical records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare carrier or intermediary manual or bulletins (including issue and date), other policies, regulations, or directives).

f. **Review Protocol.** A narrative description of how the Arterial and Vascular Procedures Review was conducted and what was evaluated.

2. **Statistical Sampling Documentation.**

a. The number of Arterial and Vascular Procedures appraised in the Sample.

b. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.

c. A description or identification of the statistical sampling software package used to select the Sample.
3. **Arterial and Vascular Procedures Review Findings.**

   a. A narrative explanation of the IRO’s findings and supporting rationale (including reasons for errors, patterns noted, etc.) regarding the Arterial and Vascular Procedures Review, including the results of the Sample.

   b. Total number of instances in which the IRO determined that the Arterial and Vascular Procedures were not medically necessary or appropriate, based on established practice guidelines and generally accepted standards of medical practice as described by the American College of Cardiology.

   c. A spreadsheet of the Arterial and Vascular Procedures Review results that includes the following information for each Arterial and Vascular Procedure appraised: type of Arterial and Vascular Procedure performed, whether the Procedure was medically necessary and appropriate, beneficiary name, beneficiary health insurance claim number, date of service, procedure code submitted, Federal health care program billed, and amount reimbursed.

4. **Systems Review.** Observations, findings, and recommendations on possible improvements to Qamar’s Arterial and Vascular Procedures and process(es).

5. **Credential.** The names and credential of the individuals who designed the statistical sampling procedures and the review methodology utilized for the Arterial and Vascular Procedures Review.

D. **Other Requirements.** The following requirements apply to any Quarterly Claims Review performed pursuant to this Appendix B.

   1. **Paid Claims without Supporting Documentation.** Any Paid Claim for which Qamar cannot produce documentation sufficient to support the Paid Claim shall be considered an error and the total reimbursement received by Qamar for such Paid Claim shall be deemed an Overpayment. Replacement sampling for Paid Claims with missing documentation is not permitted.
2. *Use of First Samples Drawn.* For the purposes of all samples discussed in this Appendix, the Paid Claims selected in each first sample shall be used (i.e., it is not permissible to generate more than one list of random samples and then select one for use with the sample).